Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Description

Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.

Resources

Name Format Description Link
21 Visit the original government dataset for complete information, documentation, and data access. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59641/

Tags

  • percutaneous-intervention
  • coronary-artery-disease
  • nih
  • antiplatelet-therapy
  • glycoprotein-inhibitors

Topics

Categories